

Ontario Cancer Research Ethics Board N2/CAREB REB SOP Addendum

OCREB has adopted the N2/CAREB REB SOPs. However, in order to reflect specific OCREB requirements, this addendum must be used in tandem with the SOP noted below*.

N2/CAREB SOP 203 – Duties of REB Members

SOP Section	OCREB Addendum
5.3. N/A	5.3.11 <ul style="list-style-type: none"> Member(s) knowledgeable in considering privacy issues: individuals competent to advise on privacy issues relevant to research;
5.3.9 REB Chair For REB approval of clinical trials approved by Health Canada, the REB approval letter which includes the REB attestation, is signed by the REB Chair or designee	5.3.9 Refer also to the OCREB Chair Terms of Reference For REB approval of clinical trials approved by Health Canada, the REB approval letter which includes the REB attestation, is signed by the REB Chair or designee via the electronic system,
5.3.10 REB Vice-Chair: The REB Vice-Chair or equivalent is responsible for performing the responsibilities of the REB Chair when the REB Chair is unable to do so, including:	5.3.10 The REB Vice-Chair or equivalent is responsible for performing the responsibilities of the REB Chair when the REB Chair is unable to do so, including: <ul style="list-style-type: none"> Additionally, the REB Chair can delegate that the Vice-Chair and/or another designated, qualified REB Member may assist them even when the Chair is available. Refer also to the OCREB Vice-Chair Terms of Reference

Revision History	
Date/Version	Summary of Changes
August 28, 2018/001	Original version.
March 21, 2025/004	5.3.9 added specificity that the REB approval letter is signed via the electronic system; 5.3.10 clarifies that the Vice-Chair/designated qualified REB member may assist even when the Chair is available.
June 5, 2026/005	5.3.10 – Added “including” and added bullet point to align with new format. Corrected spelling errors.